People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rani Therapeutics, LLC | — | Biotechnology | Series C | $111.8M | $1.8B | 2015 |
| Rani Therapeutics Holdings, Inc. | — | Biotechnology | Series C | $60.3M | $326.1M | 2025 |
Mir Hashim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mir Hashim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mir Imran | 2 | 6 |
| Dennis Ausiello | 2 | 4 |
| Svai Sanford | 2 | 2 |
| Abraham Bassan | 1 | 4 |
| Andrew Farquharson | 1 | 4 |
| Talat Imran | 1 | 2 |
| David Pyott | 1 | 2 |
| Jean-Luc Butel | 1 | 2 |
| Vasudev Bailey, M.D. | 1 | 1 |
| Lisa Rometty | 1 | 1 |
| Maulik Nanavaty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.